

Interplay of Genetic Risk Factors (*CHRNA5-CHRNA3-CHRNA4*) and Cessation Treatments in Smoking Cessation Success

Li-Shiun Chen, M.D., M.P.H., Sc.D.

Timothy B. Baker, Ph.D.

Megan E. Piper, Ph.D.

Naomi Breslau, Ph.D.

Dale S. Cannon, Ph.D.

Kimberly F. Doheny, Ph.D.

Stephanie M. Gogarten, Ph.D.

Eric O. Johnson, Ph.D.

Nancy L. Saccone, Ph.D.

Jen C. Wang, Ph.D.

Robert B. Weiss, Ph.D.

Alison M. Goate, D.Phil.

Laura Jean Bierut, M.D.

Objective: Smoking is highly intractable, and the genetic influences on cessation are unclear. Identifying the genetic factors affecting smoking cessation could elucidate the nature of tobacco dependence, enhance risk assessment, and support development of treatment algorithms. This study tested whether variants in the nicotinic receptor gene cluster *CHRNA5-CHRNA3-CHRNA4* predict age at smoking cessation and relapse after an attempt to quit smoking.

Method: In a community-based, cross-sectional study (N=5,216) and a randomized comparative effectiveness smoking cessation trial (N=1,073), the authors used Cox proportional hazard models and logistic regression to model the relationships of smoking cessation (self-reported quit age in the community study and point-prevalence abstinence at the end of treatment in the clinical trial) to three common haplotypes in the *CHRNA5-CHRNA3-CHRNA4* region defined by rs16969968 and rs680244.

Results: The genetic variants in the *CHRNA5-CHRNA3-CHRNA4* region that predict nicotine dependence also predicted a later age at smoking cessation in the community sample. In the smoking cessation trial, haplotype predicted abstinence at end of treatment in individuals receiving placebo but not among individuals receiving active medication. Haplotype interacted with treatment in affecting cessation success.

Conclusions: Smokers with the high-risk haplotype were three times as likely to respond to pharmacologic cessation treatments as were smokers with the low-risk haplotype. The high-risk haplotype increased the risk of cessation failure, and this increased risk was ameliorated by cessation pharmacotherapy. By identifying a high-risk genetic group with heightened response to smoking cessation pharmacotherapy, this work may support the development of personalized cessation treatments.

(*Am J Psychiatry* 2012; 169:735–742)

Tobacco smoking is a serious public health problem. Unfortunately, smoking is a quintessential dependence disorder, evidenced by a characteristic withdrawal syndrome and heavy, uncontrolled use (1). Cardinal manifestations of uncontrolled use are persistent use and an inability to quit successfully in a cessation attempt (1–3). Nicotine dependence is associated with both a reduced likelihood of quitting over time (4) and a rapid return to smoking following a quit attempt (3, 5–7). Therefore, identification of the factors that contribute to either sustained smoking or more rapid smoking relapse should help elucidate the causal basis of tobacco dependence, permit more accurate prediction of dependence and relapse risk, and support more effective application of treatment.

Recent meta-analyses (8–11) based on tens of thousands of subjects of European descent have confirmed the association of chromosome region 15q25.1 with smoking quan-

tity, defined by cigarettes per day; the most robust associations have been reported for rs16969968 and rs1051730, two highly correlated variants ($p < 5.57 \times 10^{-72}$) (10). In the *CHRNA5-A3-B4* region, at least two independent signals have been identified (9, 12). The first signal, tagged by rs16969968, a variant that results in an amino acid change in the α_5 nicotinic cholinergic receptor (*CHRNA5*), alters nicotinic receptor conductance in vitro (13, 14). A second, distinct signal, tagged by rs680244, is associated with variability in *CHRNA5* mRNA levels (15). Resequencing of the *CHRNA5-CHRNA3-CHRNA4* locus in subjects of European ancestry identified three common haplotypes in the region spanning *CHRNA5* and the 3' end of *CHRNA3* (12), which can be defined by rs16969968 and rs680244 (15).

The *CHRNA5-CHRNA3-CHRNA4* variants have been less consistently associated with cessation outcomes than with measures of smoking quantity. Five studies have

This article is featured in this month's AJP **Audio**, is discussed in an **Editorial** by Dr. Lotrich (p. 681), is an article that provides **Clinical Guidance** (p. 742), and is the subject of a **CME** course (p. 767)

shown an association between the *CHRNA5-CHRNA3-CHRNA4* region and successful smoking cessation (16–20). All five found that the same genetic risk variants that contribute to smoking quantity and nicotine dependence also predicted smoking cessation. Other studies, however, failed to confirm this association (21–23). A genome-wide association study of three treatment cohorts did not identify any nicotinic receptor genes as predictors of prospectively measured smoking cessation (23). One large genome-wide association meta-analysis that strongly supported the association between 15q25.1 and smoking quantity failed to find an association with smoking cessation (current versus former smoking) at a genome-wide level of significance (10).

A logical case can be made for a relation between the *CHRNA5-CHRNA3-CHRNA4* variants and smoking cessation. These variants are consistently related to measures of smoking quantity and nicotine dependence (12, 16), and there is copious evidence that measures of nicotine dependence predict cessation likelihood (4, 5, 24). These findings encourage examination of the involvement of the *CHRNA5-CHRNA3-CHRNA4* variants in cessation and further suggest that this relation is mediated by dependence. If evidence for mediation is not found and yet the variants are related to cessation, it would suggest that the variants influence cessation through routes that are independent of their influence on dependence. Moreover, previous research suggests that the relation between the *CHRNA5-CHRNA3-CHRNA4* variants and cessation should be examined with regard to pharmacotherapy. There is mounting evidence that pharmacotherapies work by mitigating the risks for cessation failure that are related to severity of nicotine dependence (25, 26). This suggests that the connection between the variants and cessation may be strongest among individuals who do not receive pharmacotherapy for smoking cessation.

Using data from a community-based project, the Atherosclerosis Risk in Communities (ARIC) study (27), and a smoking cessation clinical trial at the University of Wisconsin Transdisciplinary Tobacco Use Research Center, we extended the research on the *CHRNA5-CHRNA3-CHRNA4* region and smoking cessation success. This research was predicated on hypotheses about the relations of *CHRNA5-CHRNA3-CHRNA4* variants, tobacco dependence, and smoking cessation. The two types of studies differ in study duration, amount of experimental contact and monitoring, and type of participants. However, complementary hypotheses were developed for these two types of research designs. In the case of the ARIC community study, the assumption was that dependence would be manifest in the occurrence of cessation at a later age (28–30). In the case of the Wisconsin clinical trial, the assumption was that both heightened genetic risk and greater dependence would be demonstrated as failed abstinence at the end of treatment. Therefore, the difficulty of quitting was assessed in terms of both longer latency before quitting in a community

sample and failed abstinence at the end of treatment in a treatment trial. Analyses addressed three major questions: 1) Does the natural history of smoking cessation vary by genetic variants in the chromosome 15q25 region? 2) Do these variants predict cessation in a treatment trial? 3) Does the relation between the genetic variants and cessation depend on treatment status? The results are relevant to understanding the nature of risk posed by the targeted variants for cessation and whether the variants have pharmacogenetic implications in treatment assignment or application.

Method

Community Study

We used the ARIC study to examine the genetic association with age at cessation in a nontreatment setting. It is a prospective epidemiologic study conducted in four U.S. communities to investigate atherosclerosis. In 1987, each ARIC field center recruited a cohort sample ages 45–64 from a defined population in its community, and almost 16,000 subjects participated. Self-reported age at cessation was assessed with the question “How old were you when you stopped smoking?” Genotyping was performed on the Affymetrix 6.0 chip at the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Genetic and phenotype data were available for 12,771 subjects; data were obtained from the National Center for Biotechnology Information database of Genotypes and Phenotypes ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap; dbGaP accession number phs000090.v1.p1](http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap;dbGaP%20accession%20number%20phs000090.v1.p1)).

Smoking Cessation Clinical Trial

We used a randomized, placebo-controlled smoking cessation trial at the University of Wisconsin Center for Tobacco Research and Intervention (31) to examine the genetic association with time to relapse after quitting in a treatment trial setting. This study group has not been previously examined for the association of genetic risk with smoking cessation. The institutional review board at the University of Wisconsin–Madison approved this trial, and all subjects provided written informed consent.

Participants were eligible to participate if they were 18 years of age or older, smoked 10 or more cigarettes per day, and were motivated to quit smoking. Before randomization, the participants completed baseline assessments of demographic characteristics, smoking history (including cigarettes smoked per day), and tobacco dependence, which included the Fagerström Test for Nicotine Dependence (32). Each participant provided a breath sample for alveolar carbon monoxide analysis to verify smoking status and estimate the quantity of smoking.

The participants (N=1,073) were randomly assigned to six conditions: placebo (N=132), nicotine patch (N=187), nicotine lozenge (N=183), sustained-release bupropion (N=188), nicotine patch and nicotine lozenge (N=193), or bupropion and nicotine lozenge (N=190). All participants received six brief (10-minute) individual counseling sessions.

The point prevalence of biochemically confirmed 7-day abstinence was assessed at the end of treatment (8 weeks after quitting). All of the participants' self-reports of abstinence during study visits were confirmed by an expired carbon monoxide level of less than 10 ppm. Relapse was defined as any smoking on 7 consecutive days after the target quit date. Time of relapse was determined through timeline follow-up assessment (33, 34) and was available for 1,015 subjects.

Genotyping of the Wisconsin study group was performed by the Center for Inherited Disease Research at Johns Hopkins University and used the Illumina Omni2.5 microarray (www.illumina.com). Data cleaning was led by the Gene Environment Association Studies (GENEVA) Coordinating Center at the University of Washington.

Analysis

CHRNA5-CHRNA3-CHRNA4 haplotypes were analyzed. It is advantageous to model the genetic architecture by rational selection of haplotypes that maximizes information about the common variation at this locus and reflects potential underlying biological mechanisms. Three common haplotypes in the region spanning *CHRNA5* and the 3' end of *CHRNA3* (12, 15) are defined by rs16969968 and rs680244. The rs16969968 allele associated with risk for smoking primarily occurs on the rs680244 allele with low mRNA expression of *CHRNA5*. Together, these variants identify three risk levels involving *CHRNA5* and represent two distinct mechanisms for nicotine dependence. We used these three haplotypes as our standard of analysis: haplotype 1 (low smoking risk allele at rs16969968 and low mRNA expression allele at rs680244), haplotype 2 (low smoking risk allele at rs16969968 and high mRNA expression allele at rs680244), and haplotype 3 (high smoking risk allele at rs16969968 and low mRNA expression allele at rs680244). In the ARIC data set, these two variants were not genotyped, so two highly correlated single-nucleotide polymorphisms (SNPs) were used as proxies to estimate haplotypes: rs951266 as a proxy for rs16969968 and rs6495306 as a proxy for rs680244. In the Utah samples with northern and western Europe ancestry in the 1000 Genomes Project (<http://www.1000genomes.org/>), the correlations of these proxies with the target SNPs were $r^2=0.97$ and $r^2=1.00$, respectively.

We used PLINK (35) to estimate haplotype probabilities for each individual. We assumed that pairs of haplotypes in an individual are "additive." The posterior probability for the haplotypes was 1 for more than 99% of the haplotypes. Dummy coding for different haplotypes was used.

We used a standard series of Cox proportional hazard models to analyze age at smoking cessation in the ARIC study, and we used logistic regression to analyze the point prevalence of biochemically confirmed end-of-treatment abstinence in the Wisconsin smoking cessation trial. In the cessation trial, days to relapse constituted a secondary outcome that was analyzed with Cox proportional hazard models. The primary predictor variables of interest were haplotypes and a haplotype-by-treatment interaction in the smoking cessation study. Covariates included gender, age (in quartiles), cigarettes per day (in four levels: ≤ 10 , 11–20, 21–30, ≥ 31), and treatment (placebo versus active treatment) in the Wisconsin smoking cessation study.

Results

Community Study

Of the ARIC cohort members, 5,216 were of European descent, were identified as smokers (defined as smoking 400 cigarettes over a lifetime), and had genotype data. Demographic descriptions are given in Table S1, which accompanies the online version of this article. They smoked on average 23.6 cigarettes per day (SD=13.6) when smoking. Haplotype frequencies in the ARIC sample were as follows: G_C (24.4%), G_T (42.4%), and A_C (33.2%). The genotypes were labeled as haplotype 1, haplotype 2, and haplotype 3, respectively.

TABLE 1. Effect on Age at Smoking Cessation of Three Haplotypes in Nicotinic Receptor Gene Cluster *CHRNA5-CHRNA3-CHRNA4* in a Community Sample^a (N=5,216)

Haplotype ^b	Effect on Age at Smoking Cessation ^c		
	Relative Hazard	95% CI	p
Haplotype 1 (G_C)	Reference		
Haplotype 2 (G_T)	0.98	0.92–1.05	0.59
Haplotype 3 (A_C)	0.92	0.86–0.98	0.009

^a From the Atherosclerosis Risk in Communities Study.

^b Defined by the rs16969968 and rs680244 single-nucleotide polymorphisms. In this sample, rs951266 was used as a proxy for rs16969968 and rs6495306 was used as a proxy for rs680244. In the Utah samples with northern and western Europe ancestry in the 1000 Genomes Project (<http://www.1000genomes.org/>), the correlations of these proxies with the target SNPs were $r^2=0.97$ and $r^2=1.00$, respectively.

^c All models were adjusted for age (quartiles) and gender. Overall haplotype effect: Wald statistic=8.46, df=2, omnibus p=0.011.

We found a robust association between the *CHRNA5-CHRNA3-CHRNA4* haplotypes and smoking quantity, as defined by cigarettes per day, consistent with previous findings. These three haplotypes were strongly associated with the number of cigarettes per day (Wald statistic=56.43, df=2, omnibus p=5.8×10⁻¹³ for the overall haplotype effect) (see online Table S2).

The *CHRNA5-CHRNA3-CHRNA4* haplotypes were also associated with age at self-reported smoking cessation in this community-based sample (Wald statistic=8.46, df=2, omnibus p=0.011). Compared to haplotype 1, the high-risk haplotype 3 was associated with a later quit age (Table 1). The median age at smoking cessation was 57 years for those with haplotype 3, and it was 55 years for those with haplotype 2 or 1. The strength of this association was more modest than the association with smoking quantity. To further understand this genetic association, we added cigarettes per day as a covariate in the model. Smoking a higher number of cigarettes per day was strongly associated with a later quit age (relative hazard=0.63, 95% confidence interval [CI]=0.61–0.65, p<1.0×10⁻⁸), and the haplotypes were no longer associated with age at smoking cessation (Wald statistic=1.72, df=2, omnibus p=0.42 for the overall haplotype effect). The analyses were repeated with smoking duration (from self-reported age at onset of smoking to age at smoking cessation) as the outcome variable, and similar results were seen.

Smoking Cessation Clinical Trial

The analyses based on the trial at the University of Wisconsin Transdisciplinary Tobacco Use Research Center included 1,073 subjects of European ancestry with genotype and relapse data. Online Table S1 shows their demographic characteristics. The counts and frequencies of haplotypes 1, 2, and 3 in this group were as follows: G_C (20.8%), G_T (43.7%), and A_C (35.5%). In this treatment-seeking study group, the number of cigarettes per day was associated with the three haplotypes after adjustment for

TABLE 2. Effects on Endpoint Abstinence of Treatment and Haplotype in Nicotinic Receptor Gene Cluster *CHRNA5-CHRNA3-CHRNA4* in an 8-Week Smoking Cessation Trial^a (N=1,073)

Predictor	Effect on Abstinence at End of Treatment ^b		
	Odds Ratio	95% CI	p
Haplotype^c			
Haplotype 1 (G_C)	Reference		
Haplotype 2 (G_T)	0.62	0.33–1.17	0.14
Haplotype 3 (A_C)	0.37	0.19–0.75	0.006
Treatment status			
Placebo	Reference		
Active treatment	0.98	0.57–1.69	0.93
Interaction of haplotype and intervention^d			
Haplotype 1 and active treatment	Reference		
Haplotype 2 and active treatment	1.83	0.93–3.63	0.09
Haplotype 3 and active treatment	3.12	1.48–6.55	0.003

^a At the University of Wisconsin Transdisciplinary Tobacco Use Research Center.

^b All models were adjusted for age (quartiles) and gender.

^c Defined by the rs16969968 and rs680244 single-nucleotide polymorphisms.


^d Overall interaction effect: $\chi^2=8.97$, $df=2$, omnibus $p=0.02$.

age and gender (Wald statistic=7.15, $df=2$, omnibus $p=0.03$ for the overall haplotype effect), but this effect was modest in this heavy-smoking cohort (online Table S2).

In this trial, 47.3% of the participants were abstinent at the end of treatment (8 weeks after the quit date). In a simple logistic regression model, abstinence was predicted by treatment assignment (placebo versus active treatment) after adjustment for age and gender. Having any pharmacologic treatment, compared to placebo, increased abstinence by over 85% (odds ratio=1.87, 95% CI=1.42–2.45, $p=8.1 \times 10^{-6}$). Smoking fewer cigarettes per day was the strongest predictor of abstinence (odds ratio=0.67, 95% CI=0.60–0.75, $p=3.3 \times 10^{-11}$).

The haplotypes did not predict abstinence in the entire study group, i.e., including both placebo and treatment groups. However, the association of the haplotypes with abstinence depended on treatment condition. In the placebo group, haplotype 3, which is associated with heavy smoking, predicted failed abstinence in comparison to haplotype 1 (odds ratio=0.37, 95% CI=0.19–0.78, $p=0.009$ for haplotype 3 compared to haplotype 1); overall haplotypes were associated with abstinence ($\chi^2=7.02$, $df=2$, omnibus $p=0.03$ for the overall haplotype effect in the placebo group). However, haplotype status was not associated with abstinence among individuals receiving active pharmacotherapy ($\chi^2=1.45$, $df=2$, omnibus $p=0.48$ for the overall haplotype effect). This is reflected by a significant interaction between treatment (placebo versus active treatment) and haplotype ($\chi^2=8.97$, $df=2$, omnibus $p=0.02$ for the interaction) (Table 2, Figure 1).

FIGURE 1. Effect on Endpoint Abstinence of Interaction Between Treatment and Haplotype in Nicotinic Receptor Gene Cluster *CHRNA5-CHRNA3-CHRNA4* in an 8-Week Smoking Cessation Trial (N=1,073)^a



^a Haplotypes were defined by the rs16969968 to rs680244 single-nucleotide polymorphisms. The frequencies of haplotypes 1, 2, and 3 were 20.8%, 43.7%, and 35.5%, respectively. The interaction of haplotype and treatment was significant ($\chi^2=8.97$, $df=2$, $p=0.011$).

^b Adjusted for age and gender.

To further understand the interplay between haplotype and treatment, we added the number of cigarettes per day and the interaction between cigarettes per day and treatment to determine whether the relationship between haplotype status and abstinence depended on smoking quantity (as a measure of dependence). Heavier smoking was associated with less abstinence (odds ratio=0.67, 95% CI=0.60–0.75, $p=2.8 \times 10^{-11}$), but this relationship did not differ by treatment status ($\chi^2=0.98$, $df=1$, omnibus $p=0.32$ for the interaction). The interaction between haplotype and treatment remained significant after adjustment for cigarettes per day ($\chi^2=8.61$, $df=2$, omnibus $p=0.02$ for the interaction) (see online supplemental Table S3). In addition, we found similar results when modeling the secondary cessation outcome: time to relapse after the quit date over 60 days. There was a consistent interaction between haplotype and treatment status (haplotype 3 versus 1: relative hazard=0.54, 95% CI=0.33–0.89, $p=0.02$; haplotype 2 versus 1: relative hazard=0.60, 95% CI=0.37–0.95, $p=0.04$; overall haplotype effect: $\chi^2=6.46$, $df=2$, omnibus $p=0.04$) (see online Table S4). Figure S1 in the data supplement accompanying the online version of this article illustrates the risk for relapse by haplotype in the entire study group and in the placebo and active treatment groups. The haplotypes were associated with the risk of relapse in the placebo group but not in the active treatment group. Online Figure S2 shows the risk for relapse by treatment status, stratified by the three haplotype groups. Active treatment was strongly associated with a lower risk of relapse in individuals with haplotype 3 (relative hazard=0.48, 95%

CI=0.36–0.64, $p=9.7\times 10^{-7}$) and haplotype 2 (relative hazard=0.48, 95% CI=0.37–0.62, $p=2.7\times 10^{-8}$). Active treatment had no significant effect in those with haplotype 1 (relative hazard=0.83, 95% CI=0.56–1.24, $p=0.36$).

Furthermore, there was no significant difference in haplotypic effects on abstinence or relapse between different active treatment groups (bupropion only, nicotine replacement therapy only, and combined) (online Table S5) and no association between haplotype and abstinence or relapse in any specific active treatment group (online Figure S3 and Figure S4). Additional analyses using single SNPs showed consistent results (online Table S6 and Table S7).

Discussion

This study reveals an interaction between the genetic variants in *CHRNA5-CHRNA3-CHRNA4* and smoking cessation pharmacotherapy in relation to smoking cessation. Smokers with the high-risk haplotype had a threefold increased likelihood of responding to pharmacologic cessation treatment, compared to smokers with the low-risk haplotype.

In addition to the interaction effect, this study showed that the genetic variants in the chromosome 15q25 region that predict heavy smoking and nicotine dependence also predicted a later age at smoking cessation in a large community-based sample. Individuals with the high-risk haplotype quit later than those at low genetic risk; this difference was manifested as a 2-year delay in median quit age. Recruitment for the ARIC study began in the late 1980s, when use of nicotine replacement therapy by the general population was quite low (36, 37), so most of ARIC subjects quit smoking without any pharmacologic treatment. Thus, they represent a “natural history” of smoking cessation. The observed association between haplotype status and quitting latency was no longer significant once smoking quantity was taken into account. This suggests that the targeted risk haplotypes confer heightened risk of heavy smoking and that this, in turn, constitutes an obstacle to successful quitting.

The large smoking cessation trial offers a distinct, complementary test of the association between haplotype status and cessation. In this study, the genetic associations with smoking cessation were manifested in the placebo group, and these results are consistent with those obtained in the ARIC “natural history” sample. In contrast, these genetic variants did not predict abstinence across active treatment conditions, and the smaller genetic effect in the context of active pharmacological treatment suggests that cessation treatments differ in effectiveness across the haplotypes and mitigate the genetic risks for cessation difficulty. Pharmacological cessation treatment significantly increased the likelihood of abstinence in individuals with the high-risk haplotype, haplotype 3, but exerted little effect in individuals with the low-risk haplotype, haplotype 1.

These findings may explain discrepancies in prior studies of these genetic variants and smoking cessation. Some previous studies indicated that the chromosome 15q25 region is associated with smoking cessation (16–20), whereas other studies did not (21–23). Given our findings, we believe that genetic risk varies by pharmacologic intervention and that a weaker genetic effect (or even none) will be seen in pharmacologic trials if the effect of an interaction with treatment (active treatment versus placebo) is not included. We believe that the effect of this genetic locus will be seen most clearly in placebo arms, or in a sample where pharmacotherapy use is rare. For example, Sarginson et al. reported very little association between *CHRNA5-CHRNA3-CHRNA4* variants and cessation during the pharmacologic treatment phase of their trial, but the association increased at the 1-year follow-up after a maintenance phase with no medication (19). Our present findings suggest that an interaction of genetic risk with environment might account for such inconsistency, because the targeted genetic effects are most strongly expressed in environments that provide little support for cessation (e.g., no effective pharmacotherapy). To our knowledge, none of the previous studies has reported this interaction, which might explain the apparently inconsistent results in this area. Such interactions between genetic variants and treatment can serve as the basis for personalized medicine. The Tobacco and Genetics Consortium examined a different cessation phenotype (former versus current smoker) and reported a modest association with *CHRNA5-CHRNA3-CHRNA4* ($p<1\times 10^{-4}$) (10).

The results of this study should be interpreted in the context of several limitations. First, there was relatively little power to compare the magnitude of the targeted genetic effects among different active treatment conditions. The genetic risks for cessation were similar across the different pharmacotherapy conditions, indicating that multiple cessation interventions have the potential to be effective with such high-risk individuals. It is unclear whether pharmacotherapy mitigates particular biological processes that lead to cessation failure or whether the genetic effect is more likely expressed at high overall levels of quitting difficulty. Second, the placebo group in the cessation trial was fairly small, and this limitation adds to the importance of future replication. However, reported associations between these genetic variants and cessation in multiple groups suggest a valid relation between these variants and cessation in some environmental contexts. Third, the smoking reports in the ARIC sample were not supported by biochemical confirmation. However, such confirmation was obtained in the Wisconsin trial, and research shows that self-report is a valid indicator of current smoking, especially when there are no strong incentives to deceive (38). In addition, this work studied only one genetic locus, and it is clear that multiple genes contribute to smoking cessation success. Future research should explore whether greater accuracy in predicting treatment response can be attained by the

addition of other genetic variants implicated in differential treatment effects (39). Finally, this study included only subjects of European descent, while the frequency and effects of these genetic variants differ by ancestry.

These results suggest that the biological effects of these haplotypes affect both smoking quantity and the ability to quit, and the interaction suggests that pharmacologic treatments are more effective for individuals who are biologically predisposed to have difficulty quitting. However, it is unclear whether the haplotypes are linked to both outcomes through the same mechanisms. In the ARIC sample, the effect of the targeted haplotypes on the number of cigarettes per day mediated the influence of the haplotypes on cessation. Such mediation was not found in the Wisconsin trial, indicating that more research is needed to clarify the causal paths from the haplotypes to cessation success. However, regardless of the specific causal paths that are ultimately determined, if the *CHRNA5-CHRNA3-CHRNB4* haplotypes are indeed meaningfully related to both smoking quantity and cessation, they have an important role in the development and expression of nicotine dependence.

While acknowledging the limitations of our study, we note that this work complements and builds on previous research on treatment and genetic effects on smoking cessation. With diverse methods, this work underscores the relation between the targeted haplotypes and smoking cessation, shows a significant effect of the haplotype-treatment interaction on cessation success, and reveals that the effectiveness of cessation treatment is modulated by the haplotype.

In summary, our findings strengthen the case for the development and rigorous testing of treatments that target patients with different genetic risk profiles based on the chromosome 15q25 region that includes *CHRNA5-CHRNA3-CHRNB4*. Smokers with the high- and intermediate-risk haplotypes appear more biologically predisposed to have difficulty in quitting without treatment, but this risk may be ameliorated by effective pharmacological treatment. Further research that identifies genes associated with responsiveness to treatment for nicotine addiction may lead to treatment algorithms that further the promise of personalized medicine (40).

Received Oct. 20, 2011; revision received Feb. 7, 2012; accepted March 5, 2012 (doi: 10.1176/appi.ajp.2012.11101545). From the Department of Psychiatry and the Department of Genetics, Washington University School of Medicine, St. Louis; the Center for Tobacco Research and Intervention, School of Medicine and Public Health, University of Wisconsin, Madison; the Department of Epidemiology, Michigan State University, East Lansing; the Department of Human Genetics, Eccles Institute of Human Genetics, and the Department of Psychiatry, University of Utah School of Medicine, Salt Lake City; the Institute of Genetic Medicine, Johns Hopkins University, Baltimore; the Department of Biostatistics, University of Washington, Seattle; and the Division of Health, Social, and Economic Research, Research Triangle Institute, Research Triangle Park, N.C. Address correspondence to Dr. Chen (chenli@psychiatry.wustl.edu).

Drs. Bierut, Goate, and Wang are listed as inventors on issued U.S. patent 8,080,371, "Markers for Addiction," which covers the use of certain SNPs in determining the diagnosis, prognosis, and treatment

of addiction; no product is on the market, and no commercial interest presently exists for this patent. Dr. Goate also reports research funding for Alzheimer's disease research from AstraZeneca (\$75,000 for the last 3 years), Genentech (total \$120,000), and Pfizer (\$200,000 over 3 years) and an honorarium (\$1,000) from Pfizer for a presentation at Pfizer on Alzheimer's disease. The remaining authors report no financial relationships with commercial interests.

Supported by grants P01 CA-089392 (Dr. Bierut) and P50 CA-84724 and K05 CA-139871 (Dr. Baker) from the National Cancer Institute; grants P50 DA-19706 (Dr. Baker), R01 DA-026911 (Dr. Saccone), K02 DA-021237 (Dr. Bierut), and K08 DA-030398 (Dr. Chen) from the National Institute on Drug Abuse; grant U01 HG-004422 (Dr. Bierut) from the National Human Genome Research Institute; and subaward KL2 RR-024994 (Dr. Chen) from the National Center for Research Resources. Genotyping services for the University of Wisconsin study group were provided by the Center for Inherited Disease Research at Johns Hopkins University, and funding support for the center was provided by grant U01 HG-004438 from the National Human Genome Research Institute and NIH contract HHSN268200782096C to Johns Hopkins University. Assistance with genotype cleaning was provided by the Gene Environment Association Studies Coordinating Center, supported by grant U01 HG-004446 from the National Human Genome Research Institute. The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01 HC-55015, N01 HC-55016, N01 HC-55018, N01 HC-55019, N01 HC-55020, N01 HC-55021, N01 HC-55022, R01 HL-087641, R01 HL-59367, and R01 HL-086694; by National Human Genome Research Institute contract U01 HG-004402; and by NIH contract HHSN268200625226C. Infrastructure was partly supported by grant UL1 RR-025005 from the NIH Division of Research Resources and NIH Roadmap for Medical Research. Glaxo Wellcome provided bupropion at no cost in the University of Wisconsin Transdisciplinary Tobacco Use Research Center clinical trial.

The authors thank the Wisconsin State Laboratory of Hygiene for technical assistance; John Budde and Nick McKenna for technical assistance with Open Array platform genotyping; Louis Fox, Joseph Mullaney, and Thomas Przybeck for assistance in preparing and analyzing the data; and Sherri Fisher for assistance in coordinating the project and editing/preparing the manuscript.

References

1. Breslau N, Johnson EO, Hiripi E, Kessler R: Nicotine dependence in the United States: prevalence, trends, and smoking persistence. *Arch Gen Psychiatry* 2001; 58:810–816
2. Hughes JR, Baker T, Breslau N, Covey L, Shiffman S: Applicability of DSM criteria to nicotine dependence. *Addiction* 2011; 106:894–895; discussion 895–897
3. West R: Defining and assessing nicotine dependence in humans, in *Understanding Nicotine and Tobacco Addiction: Novartis Foundation Symposium* 275. Edited by Bock G, Goode J. Chichester, UK, John Wiley & Sons, 2005, pp 36–58
4. Breslau N, Johnson EO: Predicting smoking cessation and major depression in nicotine-dependent smokers. *Am J Public Health* 2000; 90:1122–1127
5. Baker TB, Piper ME, McCarthy DE, Bolt DM, Smith SS, Kim SY, Colby S, Conti D, Giovino GA, Hatsukami D, Hyland A, Krishnan-Sarin S, Niaura R, Perkins KA, Toll BA: Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. *Nicotine Tob Res* 2007; 9(suppl 4):S555–S570
6. Hendricks PS, Prochaska JJ, Humfleet GL, Hall SM: Evaluating the validities of different DSM-IV-based conceptual constructs of tobacco dependence. *Addiction* 2008; 103:1215–1223
7. Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T: Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. *Drug Alcohol Depend* 1994; 34:211–216
8. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, Berrettini W, Knouff CW, Yuan X, Waeber G, Vollenweider

- P, Preisig M, Wareham NJ, Zhao JH, Loos RJ, Barroso I, Khaw KT, Grundy S, Barter P, Mahley R, Kesaniemi A, McPherson R, Vincent JB, Strauss J, Kennedy JL, Farmer A, McGuffin P, Day R, Matthews K, Bakke P, Gulsvik A, Lucae S, Ising M, Brueckl T, Horstmann S, Wichmann HE, Rawal R, Dahmen N, Lamina C, Polasek O, Zgaga L, Huffman J, Campbell S, Kooner J, Chambers JC, Burnett MS, Devaney JM, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Epstein S, Wilson JF, Wild SH, Campbell H, Vitart V, Reilly MP, Li M, Qu L, Wilensky R, Matthaï W, Hakonarson HH, Rader DJ, Franke A, Wittig M, Schäfer A, Uda M, Terracciano A, Xiao X, Busonero F, Scheet P, Schlessinger D, St Clair D, Rujescu D, Abecasis GR, Grabe HJ, Teumer A, Völzke H, Petersmann A, John U, Rudan I, Hayward C, Wright AF, Kolcic I, Wright BJ, Thompson JR, Balmforth AJ, Hall AS, Samani NJ, Anderson CA, Ahmad T, Mathew CG, Parkes M, Satsangi J, Caulfield M, Munroe PB, Farrall M, Dominiczak A, Worthington J, Thomson W, Eyre S, Barton A, Wellcome Trust Case Control Consortium, Mooser V, Francks C, Marchini J: Meta-analysis and imputation refines the association of 15q25 with smoking quantity. *Nat Genet* 2010; 42:436–440
9. Saccone NL, Culverhouse RC, Schwantes-An TH, Cannon DS, Chen X, Cichon S, Giegling I, Han S, Han Y, Keskitalo-Vuokko K, Kong X, Landi MT, Ma JZ, Short SE, Stephens SH, Stevens VL, Sun L, Wang Y, Wenzlaff AS, Aggen SH, Breslau N, Broderick P, Chatterjee N, Chen J, Heath AC, Heliovaara M, Hoft NR, Hunter DJ, Jensen MK, Martin NG, Montgomery GW, Niu T, Payne TJ, Peltonen L, Pergadia ML, Rice JP, Sherva R, Spitz MR, Sun J, Wang JC, Weiss RB, Wheeler W, Witt SH, Yang BZ, Caporaso NE, Ehringer MA, Eisen T, Gapstur SM, Gelernter J, Houlston R, Kaprio J, Kendler KS, Kraft P, Leppert MF, Li MD, Madden PA, Nothen MM, Pillai S, Rietschel M, Rujescu D, Schwartz A, Amos CI, Bierut LJ: Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. *PLoS Genet* 2010; 6(8):e1001053
 10. Tobacco and Genetics Consortium: Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nat Genet* 2010; 42:441–447
 11. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, Sulem P, Rafnar T, Esko T, Walter S, Gieger C, Rawal R, Mangino M, Prokopenko I, Magi R, Keskitalo K, Gudjonsdottir IH, Gretarsdottir S, Stefansson H, Thompson JR, Aulchenko YS, Nelis M, Aben KK, den Heijer M, Dirksen A, Ashraf H, Soranzo N, Valdes AM, Steves C, Uitterlinden AG, Hofman A, Tonjes A, Kovacs P, Hottenga JJ, Willemsen G, Vogelzang N, Doring A, Dahmen N, Nitz B, Pergadia ML, Saez B, De Diego V, Lezcano V, Garcia-Prats MD, Ripatti S, Perola M, Kettunen J, Hartikainen AL, Pouta A, Laitinen J, Isohanni M, Huei-Yi S, Allen M, Krestyaninova M, Hall AS, Jones GT, van Rij AM, Mueller T, Dieplinger B, Haltmayer M, Jonsson S, Matthiasson SE, Oskarsson H, Tyrffingson T, Kiemeny LA, Mayordomo JI, Lindholt JS, Pedersen JH, Franklin WA, Wolf H, Montgomery GW, Heath AC, Martin NG, Madden PA, Giegling I, Rujescu D, Jarvelin MR, Salomaa V, Stumvoll M, Spector TD, Wichmann HE, Metspalu A, Samani NJ, Penninx BW, Oostra BA, Boomsma DI, Tiemeier H, van Duijn CM, Kaprio J, Gulcher JR, McCarthy MI, Peltonen L, Thorsteinsdottir U, Stefansson K: Sequence variants at CHRN3-CHRNA6 and CYP2A6 affect smoking behavior. *Nat Genet* 2010; 42:448–453
 12. Weiss RB, Baker TB, Cannon DS, von Niederhausern A, Dunn DM, Matsunami N, Singh NA, Baird L, Coon H, McMahon WM, Piper ME, Fiore MC, Scholand MB, Connett JE, Kanner RE, Gahring LC, Rogers SW, Hoidal JR, Leppert MF: A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. *PLoS Genet* 2008; 4(7):e1000125
 13. Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Gruzza RA, Xuei X, Saccone NL, Saccone SF, Bertelsen S, Fox L, Horton WJ, Breslau N, Budde J, Cloninger CR, Dick DM, Foroud T, Hatsukami D, Hesselbrock V, Johnson EO, Kramer J, Kuperman S, Madden PAF, Mayo K, Nurnberger J Jr, Pomerleau O, Porjesz B, Reyes O, Schuckit M, Swan G, Tischfield JA, Edenberg HJ, Rice JP, Goate AM: Variants in nicotinic receptors and risk for nicotine dependence. *Am J Psychiatry* 2008; 165:1163–1171
 14. Kuryatov A, Berrettini W, Lindstrom J: Acetylcholine receptor (AChR) alpha5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (alpha4beta2)alpha5 AChR function. *Mol Pharmacol* 2011; 79:119–125
 15. Wang JC, Cruchaga C, Saccone NL, Bertelsen S, Liu P, Budde JP, Duan W, Fox L, Gruzza RA, Kern J, Mayo K, Reyes O, Rice J, Saccone SF, Spiegel N, Steinbach JH, Stitzel JA, Anderson MW, You M, Stevens VL, Bierut LJ, Goate AM: Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. *Hum Mol Genet* 2009; 18:3125–3135
 16. Baker TB, Weiss RB, Bolt D, von Niederhausern A, Fiore MC, Dunn DM, Piper ME, Matsunami N, Smith SS, Coon H, McMahon WM, Scholand MB, Singh N, Hoidal JR, Kim SY, Leppert MF, Cannon DS: Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. *Nicotine Tob Res* 2009; 11:785–796
 17. Freathy RM, Ring SM, Shields B, Galobardes B, Knight B, Weedon MN, Smith GD, Frayling TM, Hattersley AT: A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRN4) is associated with a reduced ability of women to quit smoking in pregnancy. *Hum Mol Genet* 2009; 18:2922–2927
 18. Munafo MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P: CHRNA3 rs1051730 genotype and short-term smoking cessation. *Nicotine Tob Res* 2011; 13:982–988
 19. Sarginson JE, Killen JD, Lazzaroni LC, Fortmann SP, Ryan HS, Schatzberg AF, Murphy GM Jr: Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. *Am J Med Genet B Neuropsychiatr Genet* 2011; 156B:275–284
 20. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, Kaprio J, Lerman C, Park PW: Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. *Neuropsychopharmacology* 2012; 37:641–650
 21. Breiting LP, Twardella D, Hoffmann MM, Witt SH, Treutlein J, Brenner H: Prospective association of dopamine-related polymorphisms with smoking cessation in general care. *Pharmacogenomics* 2010; 11:527–536
 22. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, Bergen AW, Swan GE, Tyndale RF, Benowitz NL, Lerman C: Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. *Hum Mol Genet* 2008; 17:2834–2848
 23. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, David SP, Niaura R, Lerman C: Molecular genetics of successful smoking cessation: convergent genome-wide association study results. *Arch Gen Psychiatry* 2008; 65:683–693
 24. Piper ME, McCarthy DE, Baker TB: Assessing tobacco dependence: a guide to measure evaluation and selection. *Nicotine Tob Res* 2006; 8:339–351
 25. Loh WY, Piper ME, Schlam TR, Fiore MC, Smith SS, Jorenby DE, Cook JW, Bolt DM, Baker TB: Should all smokers use combination smoking cessation pharmacotherapy? using novel analytic methods to detect differential treatment effects over 8 weeks of pharmacotherapy. *Nicotine Tob Res* 2012; 14:131–141
 26. Stapleton JA, Sutherland G: Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial. *Addiction* 2011; 106:824–832
 27. Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW, McGovern P, Nieto FJ, Tell GS: Cigarette smoking and progres-

- sion of atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. *JAMA* 1998; 279:119–124
28. Croghan IT, Hurt RD, Ebbert JO, Croghan GA, Polk OD, Stella PJ, Novotny PJ, Sloan J, Loprinzi CL: Racial differences in smoking abstinence rates in a multicenter, randomized, open-label trial in the United States. *Z Gesundh Wiss* 2010; 18:59–68
 29. Frosch ZA, Dierker LC, Rose JS, Waldinger RJ: Smoking trajectories, health, and mortality across the adult lifespan. *Addict Behav* 2009; 34:701–704
 30. Levy DT, Romano E, Mumford E: The relationship of smoking cessation to sociodemographic characteristics, smoking intensity, and tobacco control policies. *Nicotine Tob Res* 2005; 7:387–396
 31. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, Baker TB: A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Arch Gen Psychiatry* 2009; 66:1253–1262
 32. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO: The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. *Br J Addiction* 1991; 86:1119–1127
 33. Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, Baker TB: Efficacy of bupropion alone and in combination with nicotine gum. *Nicotine Tob Res* 2007; 9:947–954
 34. Sobell LC, Sobell MB: Timeline follow-back: a technique for assessing self-reported alcohol consumption, in *Measuring Alcohol Consumption: Psychosocial and Biological Methods*. Edited by Litten RZ, Allen J. Totowa, NJ, Humana Press, 1992, pp 41–72
 35. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; 81:559–575
 36. Alberg AJ, Patnaik JL, May JW, Hoffman SC, Gitchelle J, Comstock GW, Helzlsouer KJ: Nicotine replacement therapy use among a cohort of smokers. *J Addict Dis* 2005; 24:101–113
 37. Centers for Disease Control and Prevention: Use of FDA-approved pharmacologic treatments for tobacco dependence—United States, 1984–1998. *MMWR Morb Mortal Wkly Rep* 2000; 49:665–668
 38. SRNT Subcommittee on Biochemical Verification: Biochemical verification of tobacco use and cessation. *Nicotine Tob Res* 2002; 4:149–159
 39. Berrettini WH, Wileyto EP, Epstein L, Restine S, Hawk L, Shields P, Niaura R, Lerman C: Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. *Biol Psychiatry* 2007; 61:111–118
 40. Rutter JL: Symbiotic relationship of pharmacogenetics and drugs of abuse. *AAPS J* 2006; 8(1):E174–E184

Clinical Guidance: Genetic Risk Factors (*CHRNA5-CHRNA3-CHRN4*) and Smoking Cessation Treatment

Chen et al. separated smokers by their nicotinic receptor gene variants. Those with the low-risk genotype responded equally well to pharmacological treatments, including both nicotine replacement and bupropion, and nonpharmacological therapies. Those with the high-risk genotype, as identified by DNA sequencing, responded only to pharmacological treatments. Clinicians advising patients on smoking cessation can suspect genetic risk on the basis of early onset of heavy smoking and direct those smokers specifically to pharmacological treatments. Lotrich in an editorial (p. 681) points out that the chance of quitting successfully rises from about 25% to about 50% in patients with the high-risk genetic variant if they are treated with nicotine, bupropion, or their combination.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.